




ARCHIVOS DE Bronconeumología

www.archbronconeumol.org



Scientific Letter

Risk of Exposure for the Caregivers During Aminoglycoside Nebulization: An Observational Study

To the Director,

According to estimates from 2019, more than one million of deaths and economic costs around the world are annually attributable to antibiotics-resistant infections.¹ Thus, the antimicrobial resistance is challenging for the public health, even if the risk assessment is not frequent and the real exposure risk is difficult to evaluate.²

Despite, the advent of CFTR modulators, the infections treatment with antibiotics remains a cornerstone of the treatment for many patients with CF (PwCF). For many years, they have been delivered by inhalation with the advantage to bypass the alveolar-capillary barrier and to favor the lung penetration.³

The risk related to the occupational exposure to the antibiotics has scarcely been studied, even if some side-effects were demonstrated in nurses.^{4–6} The exposure of proxy related to the nebulization of antibiotics has never been investigated. However, fugitive aerosol is emitted from the nebulizer, during both inspiration and expiration in the environment (medical aerosol), and by the patient during expiration (bioaerosol). The people circulating around the patient could be occupationally exposed to this fugitive aerosol. Our hypothesis was that the urine of caregivers would contain a detectable amount of the nebulized antibiotics in such conditions. The aim of this study was to observe the risk of exposure to the nebulized antibiotics by measuring the aminoglycosides concentration in the urine of parents of PwCF performing nebulization of aminoglycosides.

This prospective observational study was conducted in the caregivers of the children with CF in accordance with the Declaration of Helsinki and the current guidelines for Clinical Good Practice. The study was approved by the local ethics committee (B4032023000087). All caregivers accompanying a pediatric PwCF for a routine visit in the CF center were eligible and prospectively assessed. To be included, the caregiver had to be an adult circulating at less than 5 m of the PwCF for at least 3 min during the last nebulization before the visit. The PwCF had to nebulize an aminoglycoside at home in the last 6 h before the time of the visit. The caregivers were excluded if they used aminoglycosides in the last week and if they are known to have a renal insufficiency.

The endpoint was the concentration of the nebulized antibiotic in the urinary excretion of the caregivers. All the measurements were carried out in the morning. The caregivers were requested to provide a urine sample (at least 20 mL) which was immediately frozen at -80°C and stored. Urinary aminoglycoside concentration was assessed by the fluorescence polarization immunoassay method in replicate. The threshold detection was 0.8 and 0.33 $\mu\text{g/dL}$

for amikacin (AMIK2 insert, ROCHE diagnostics) and tobramycin (TOBR2 insert, ROCHE diagnostics), respectively.

Fifty-five PwCF were eligible during the recruitment period. Twenty-three caregivers (10 fathers and 13 mothers) for 23 PwCF met the inclusion criteria and the others did not perform the last nebulization session. Five caregivers refused to participate because of lack of time. The characteristics of the PwCF and proxy are highlighted in Table 1. The FEV₁ of the 10 PwCF who were able to perform a lung function test in routine was in the normal range. A potential relationship between the lung function and the exposure was not possible to be verified. Four PwCF were doing all the nebulization session on the knees of the caregivers. All the PwCF older than 3 years ($n=14$) were performing the nebulization with a mouthpiece as recommended in our center and the others were using a facemask. The PwCF were using a jet (Sidestream and PortaNeb, Philips Respironics) ($n=8$) or a vibrating mesh nebulizer (eFlow, Pari) ($n=10$). The duration of the session was approximately 15 min and 8 min for the jet and the mesh nebulizer, respectively, and the minimal use duration of nebulized aminoglycosides was 6 months. Four of the recruited caregivers were preparing the drug to be nebulized. No room were ventilated by opening the window.

The median delay from the last exposure was 190 min (40–300 min) and the median distance from the nebulizer was 2 m (0.5–5 m). The nebulized aminoglycosides were tobramycin (40 mg/4 mL and 80 mg/4 mL for <5 years and 5–10 years, respectively) ($n=15$) and amikacin (250 mg/4 mL) ($n=3$). Eight samples out of the 18 were positive for aminoglycosides, none of them for amikacin. Fifty percent of the caregivers staying the full nebulization session close to the PwCF were positive for aminoglycoside. None of the caregivers reported any adverse effects related to the session (bronchospasm, cough, etc.).

The exposure to the fugitive aerosol from the nebulization was not surprising because an exposure to airborne particles has been previously documented in the firefighters at the World Trade Center⁷ and the vessel crew.⁸ Health care workers are also occupationally exposed to airborne particles.⁹ Occupational exposure was demonstrated during the delivery of nebulized pentacarinat.^{10,11} Even if data were not available concerning environmental contamination through use of other aerosolized antibiotics, a potential environmental contamination inherent in the usual aerosol technique was suggested.¹²

During the nebulization, aerosolized droplets are three-dimensionally emitted in the air over variable angle and distance depending on the size of the particles,¹³ and on the speed of the airflow.¹⁴ Depending on their size, the emitted particles leave (diameter higher than the respirable diameter) or remain within the vortex associated to the jet because the gravitational force.¹³ The particle levels in the air decay with the particle mass, the distance from the nebulizer and the time after the nebulization.^{15,16}

<https://doi.org/10.1016/j.arbres.2025.01.011>

0300-2896/© 2025 SEPAR. Published by Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Table 1
Descriptive Data About the Participants and the Experimental Conditions, and Results Related to the Exposure.

Subjects	Aminoglycoside	Last Nebulization (h)	Last Miction (h)	Distance of Exposure From the Nebulizer (m)	Age of the Patient (Year)	Age of the Caregiver (Year)	Creatinine ($\mu\text{g/dL}$)	Detection of Aminoglycoside ($\mu\text{g/dL}$)
1	Tobramycin	4	1	3	6	30	239.1	–
2	Tobramycin	3	0.5	0.5	4	35	59.2	0.41
3	Tobramycin	2	0.5	1	2	29	323.2	–
4	Tobramycin	3	2	4	3	26	67.3	–
5	Tobramycin	1.5	2	5	8	34	27.2	0.34
6	Tobramycin	2	1	0.5	2	29	131.6	0.42
7	Tobramycin	2	0.25	4	3	27	188.5	0.52
8	Tobramycin	2	0.25	1	3	31	24.8	–
9	Tobramycin	3	0.5	2	8	42	165.1	–
10	Tobramycin	3	0.3	3	0.9	31	85.5	–
11	Tobramycin	3	1	3	1	29	120.7	0.51
12	Tobramycin	4	1	1	7	40	100.3	0.37
13	Tobramycin	5	0.5	2	10	42	178.6	–
14	Tobramycin	3	1	3	4	36	68.6	0.37
15	Tobramycin	5	2	4	3	32	102.1	0.41
16	Amikacin	0.6	2	1	16	35	85.1	–
17	Amikacin	0.6	3	2	15	47	130.1	–
18	Amikacin	1.5	3	2	16	23	102.9	–

Threshold detection for amikacin and tobramycin: 0.8 and 0.33 $\mu\text{g/dL}$, respectively.
Gray color: detected aminoglycoside in the urine of the caregiver.

Our results have to be nuanced based on all these elements. The air-flow was not possibly include in the interpretation because only 10 PwCF were able to perform a spirometry. The exposure was mainly a short-range airborne exposure because the small particles emitted in the air by the used nebulizers (respirable because mainly around 3–5 μm) and the short distance of the caregivers from the nebulizer during the session (lower than 5 m).

Aminoglycosides are concentration-dependent antibiotics and their concentration in the urine of non-exposed subjects is expected to be undetectable. As the amikacin is excreted unchanged from the serum in the urine (more than 80%) in less than 9 h,¹⁷ the concentration found in the urine should be close to or lower than its serum concentration. Then, it reflects the systemic exposure of the caregivers. The observed risks related to exposure are not benign. Even if it is expected to be associated to high serum concentrations, ototoxicity related to nebulized amikacin was demonstrated with a unpredictable genetic predisposition related to the MT-RNR1 gene.¹⁸ Similarly, a nephrotoxicity has been observed.¹⁹ Moreover, the repeated nebulizations of aminoglycoside and the resulting exposure of the caregivers could contribute to the modification of the airway resistome.²⁰ Finally, prior antibiotic caregiver's exposure to antibiotics could produce in the future a detrimental effect on response to immune checkpoint inhibitors because the gut microbial imbalance is mediated by antibiotics.²¹

Some limits to the study have to be addressed. First, the time between nebulization and urine sampling was variable. However, due to the short half-life of the aminoglycosides and the aim of assessing the exposure, we hypothesized that if the caregivers were exposed to the fugitive aerosol, the maximal 6 h-delay between the nebulization and the sampling was optimal to avoid the disappearance of the urine aminoglycoside before sampling and then demonstrated the exposure. The aminoglycosides air concentration related to the exposure of the caregivers was evidently not similar for all of them due to the limits of the protocol (variable distance and duration of exposure, uncontrolled aeration of the room, participation to the preparation of the nominal dose) of this real-life study.

In conclusion, the caregivers are importantly exposed to the fugitive aerosol during a nebulization session even when they are not involved in the nebulization itself. In case of antibiotics nebulization, the importance of this risk has to be considered. This risk could justify modifying the routine related to the nebuliza-

tion of antibiotics in the future by adding an expiratory filter to the nebulizer or by prioritizing other methods of administration (dry powder or pressurized-metered dose inhalers) even if further studies related to these changes are needed.

Contribution

Gregory Reyhler, Conception and realization of the study, analysis of the results, and writing of the manuscript.

Zoé Verdereau, Conception and realization of the study, analysis of the results, and correction and approbation of the manuscript.

Anne-Sophie Aubriot, Conception of the study, analysis of the results, and correction and approbation of the manuscript.

Sophie Gohy, Conception of the study, analysis of the results, and correction and approbation of the manuscript.

Silvia Berardis, Conception of the study, analysis of the results, and correction and approbation of the manuscript.

Lidvine Boland, Conception of the study, analysis of the results, and correction and approbation of the manuscript.

Vincent Haufroid, Conception of the study, analysis of the results, and correction and approbation of the manuscript.

Jean-Christophe Dubus, Conception and realization of the study, analysis of the results, and writing of the manuscript.

Ethical Approval

B4032023000087.

Artificial Intelligence Involvement

No involvement.

Funding

No funding for the study. Gregory Reyhler received a grant from the Institut de Recherche Expérimentale et Clinique (Université catholique de Louvain – Brussels – Belgium). Sophie Gohy is a researcher clinician of the Fonds National de la Recherche Scientifique (FNRS; grant 1R01618).

Conflicts of Interest

No conflict of interest.

References

1. Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399(10325):629–55.
2. Graham DW, Bergeron G, Bourassa MW, et al. Complexities in understanding antimicrobial resistance across domesticated animal, human, and environmental systems. *Ann N Y Acad Sci*. 2019;1441:17–30.
3. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W. Inhalation of antibiotics in cystic fibrosis. *Eur Respir J*. 1995;8:1594–604.
4. Pinheiro V, Pestana C, Pinho A, Antunes I, Goncalo M. Occupational allergic contact dermatitis caused by antibiotics in healthcare workers – relationship with non-immediate drug eruptions. *Contact Dermatitis*. 2018;78:281–6.
5. Merget R, Sander I, Fartasch M, et al. Occupational generalized urticaria and anaphylaxis after inhalation of cefuroxime in a nurse. *Am J Ind Med*. 2018;61:261–6.
6. Loeb MB, Craven S, McGeer AJ, et al. Risk factors for resistance to antimicrobial agents among nursing home residents. *Am J Epidemiol*. 2003;157:40–7.
7. Banauch GI, Alleyne D, Sanchez R, et al. Persistent hyperreactivity and reactive airway dysfunction in firefighters at the World Trade Center. *Am J Respir Crit Care Med*. 2003;168:54–62.
8. Budnik LT, Wegner R, Rogall U, Baur X. Accidental exposure to polychlorinated biphenyls (PCB) in waste cargo after heavy seas. *Global waste transport as a source of PCB exposure*. *Int Arch Occup Environ Health*. 2014;87:125–35.
9. Thibon C, Vecellio L, Belkhir L, et al. There is a risk of spread during a nebulization session in a patient with COVID-19. *J Aerosol Med Pulm Drug Deliv*. 2023;36:268–74.
10. Stanbury M, Gatti E, Sokolowski JW. Reactive airways dysfunction syndrome in a nurse exposed to pentamidine. *J Occup Environ Med*. 1996;38:330–1.
11. Balmes JR, Estacio PL, Quinlan P, Kelly T, Corkery K, Blanc P. Respiratory effects of occupational exposure to aerosolized pentamidine. *J Occup Environ Med*. 1995;37:145–50.
12. Prober CG, Walson PD, Jones J. Technical report: precautions regarding the use of aerosolized antibiotics. *Pediatrics*. 2000;106:art-art89.
13. Wei J, Li Y. Human cough as a two-stage jet and its role in particle transport. *PLOS ONE*. 2017;12:e0169235.
14. Berlanga FA, Olmedo I, Ruiz de AM. Experimental analysis of the air velocity and contaminant dispersion of human exhalation flows. *Indoor Air*. 2017;27:803–15.
15. Dhanak M, Verma S, Hughes PG, et al. The laboratory characterization of fugitive aerosol emissions from a standard jet nebulizer with and without a filtered mouthpiece. *Cureus*. 2023;15:e50611.
16. Hui DS, Chow BK, Chu LCY, et al. Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. *Chest*. 2009;135:648–54.
17. Rubino CM, Onufrak NJ, van Ingen J, et al. Population pharmacokinetic evaluation of amikacin liposome inhalation suspension in patients with treatment-

refractory nontuberculous mycobacterial lung disease. *Eur J Drug Metab Pharmacokinet*. 2021;46:277–87.

18. Gaafar D, Baxter N, Cranswick N, Christodoulou J, Gwee A. Pharmacogenetics of aminoglycoside-related ototoxicity: a systematic review. *J Antimicrob Chemother*. 2024;79:1508–28.
19. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. *Kidney Int*. 2011;79:33–45.
20. Mac Aogain M, Xaverius Ivan F, Jaggi TK, et al. Airway “resistotypes” and clinical outcomes in bronchiectasis. *Am J Respir Crit Care Med*. 2024;210:47–62.
21. McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve therapeutic response in cancer. *Lancet Oncol*. 2019;20:e77–91.

Gregory Reyhler^{a,b,c,d,*}, Zoé Verdereau^a,
Anne-Sophie Aubriot^{b,e}, Sophie Gohy^{c,d,e}, Silvia Berardis^e,
Lidvine Boland^{f,g}, Vincent Haufroid^{f,g}, Jean-Christophe Dubus^{h,i}

^a Département de kinésithérapie, VINCI, Brussels, Belgium

^b Service de Kinésithérapie et Ergothérapie, Cliniques Universitaires Saint-Luc, Brussels, Belgium

^c Institut de recherche expérimentale et clinique (IREC), pôle de Pneumologie, ORL et Dermatologie, Université Catholique de Louvain, Brussels, Belgium

^d Service de Pneumologie, Cliniques universitaires Saint-Luc, Brussels, Belgium

^e Centre de référence pour la mucoviscidose, Cliniques universitaires Saint-Luc, Brussels, Belgium

^f Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium

^g Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Louvain-la-Neuve, Belgium

^h Pneumologie et allergologie pédiatrique, CHU Timone-Enfants, Marseille, France

ⁱ Aix-Marseille Université, C2VN, INSERM 1263-INRAE 1260, Marseille, France

*Corresponding author.

E-mail address: gregory.reyhler@uclouvain.be (G. Reyhler).